Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

NCT04537234 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza (Healthy Volunteers)

Interventions

BIOLOGICAL: High-Dose Quadrivalent Influenza Vaccine
BIOLOGICAL: Standard-Dose Quadrivalent Influenza Vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company